Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:06 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 14,746 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Pulmonary Clear all

Conditions: COVID-19
Interventions: Not listed
Lead sponsor: Synairgen Research Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Coronavirus Disease (COVID-19)
Interventions: Molnupiravir, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 20
States / cities: Harbor City, California • Los Angeles, California • Sacramento, California + 17 more

Conditions: Asthma
Interventions: Fluticasone Furoate/ Vilanterol 200/25 mcg, Fluticasone Furoate/ Vilanterol 100/25 mcg, Fluticasone Furoate 100 mcg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 1,040 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 37
States / cities: Little Rock, Arkansas • Huntington Beach, California • Los Angeles, California + 33 more

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: pirfenidone; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 40 Years to 84 Years
Enrollment: 1,058 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: South San Francisco, California

Conditions: Immune Checkpoint Inhibitors, Metastatic Solid Tumor, Nonsmall Cell Lung Cancer, Melanoma, Renal Cell Carcinoma, Gastrointestinal Cancer, Squamous Cell Carcinoma
Interventions: Immunotherapy; Biological
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 99 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 6
States / cities: Tucson, Arizona • Albuquerque, New Mexico • Oklahoma City, Oklahoma + 3 more

Conditions: Cystic Fibrosis, Diabetes Mellitus
Interventions: Stable isotopes; Other
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: COVID-19 Vaccines
Interventions: BNT162b2; Biological
Lead sponsor: BioNTech SE; Industry
Eligibility: 5 Years and older
Enrollment: 700 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 14
States / cities: Homestead, Florida • Miami Lakes, Florida • Atlanta, Georgia + 10 more

Conditions: Covid19
Interventions: Questionnaires; Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis, Lung Disease
Interventions: Interferon gamma-1b; Drug
Lead sponsor: InterMune; Industry
Eligibility: Not listed
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Brisbane, California

Conditions: Advanced Solid Tumor, Non Small Cell Lung Cancer, Colorectal Cancer
Interventions: DSP107, Atezolizumab; Biological
Lead sponsor: Kahr Medical; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 7
States / cities: La Jolla, California • Aurora, Colorado • Lake Mary, Florida + 4 more

Conditions: Non Small Cell Lung Cancer
Interventions: Ixabepilone, Cisplatin; Drug
Lead sponsor: R-Pharm; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • New Brunswick, New Jersey • Hershey, Pennsylvania

Conditions: Breast Cancer, Pancreatic Cancer, Colorectal Cancer, Carcinoma, Non-Small-Cell Lung, Adenocarcinoma
Interventions: MORAb-066; Drug
Lead sponsor: Morphotek; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 2
States / cities: Oklahoma City, Oklahoma • Nashville, Tennessee

Conditions: Mesothelioma, Mesotheliomas Pleural, Mesothelioma, Malignant, Mesothelioma Peritoneum, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Pancreatic Cancer, Pancreatic Adenocarcinoma, Colorectal Cancer, Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Ovarian Adenocarcinoma, Pancreatic Neoplasms, Colorectal Neoplasms, Ovarian Neoplasms, Cholangiocarcinoma, Non Small Cell Lung Cancer
Interventions: TC-510, Fludarabine, Cyclophosphamide; Biological · Drug
Lead sponsor: TCR2 Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 7
States / cities: San Franciso, California • Miami, Florida • Bethesda, Maryland + 4 more

Conditions: Non-small Cell Lung Cancer
Interventions: custirsen sodium; Drug
Lead sponsor: Achieve Life Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 6
States / cities: Los Angeles, California • Albany, New York • Portland, Oregon + 2 more

Conditions: Alpha 1-Antitrypsin Deficiency
Interventions: Not listed
Lead sponsor: Biocerna LLC; Industry
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Fulton, Maryland

Conditions: Lung Cancer, Small Cell
Interventions: topotecan; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 6
States / cities: Lebanon, New Hampshire • The Bronx, New York • Philadelphia, Pennsylvania + 3 more

Conditions: Cystic Fibrosis
Interventions: Nitric Oxide 160 ppm; Drug
Lead sponsor: Novoteris, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 6
States / cities: Garden Grove, California • Los Angeles, California • Columbus, Ohio + 3 more

Conditions: Progressive Pulmonary Fibrosis, Interstitial Lung Disease
Interventions: Placebo, Inhaled Treprostinil, Treprostinil Ultrasonic Nebulizer; Drug · Device
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 698 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 74
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 60 more

Conditions: Asthma
Interventions: ADVAIR HFA, ADVAIR DISKUS; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 4 Years to 11 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 3
States / cities: Huntington Beach, California • Long Beach, California • Medford, Oregon

Conditions: Non-small Cell Lung Cancer
Interventions: Stereotactic Body Radiation Therapy (SBRT), cisplatin or carboplatin-based; Radiation · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2024
U.S. locations: 8
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: Nintedanib; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 66 Years and older
Enrollment: 1,798 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Milton, Massachusetts

Conditions: Breast Cancer, Lung Cancer, Genito Urinary Cancer
Interventions: End-of-life conversation game called "Hello"; Other
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Cystic Fibrosis
Interventions: VX-828, Placebo, Itraconazole, Midazolam, Tezacaftor, VX-118, Deutivacaftor; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 12
States / cities: Hollywood, Florida • Orlando, Florida • Overland Park, Kansas + 9 more

Conditions: Granulomatosis With Polyangiitis, Microscopic Polyangiitis
Interventions: Observational; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 12 Years to 100 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 7
States / cities: Birmingham, Alabama • Baltimore, Maryland • Boston, Massachusetts + 4 more

Search by objective public record fields.

Pilot Test of COVID-19 Related Clinical Outcome Assessment Methodology and Qualitative Evidence of Content Validity

Efficacy and Safety of Molnupiravir (MK-4482) in Hospitalized Adult Participants With COVID-19 (MK-4482-001)

An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol (FF/VI) 200/25 Microgram (mcg) , FF/VI 100/25 mcg, and FF 100 mcg in Adults and Adolescents With Persistent Asthma.

Open-Label Study of the Long Term Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population

Increased Gluconeogenesis is One Cause of Cystic Fibrosis Related Diabetes (CFRD)

A Study of COVID-19 Vaccine(s) in Children and Adults

COVID-19 Survivorship Registry

An Open-Label Study of the Safety of Interferon Gamma-1b in Patients With IPF

A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors

Phase I Combination Ixabepilone + Cisplatin

Dose Escalation Study MORAb-066 Targeting Tissue Factor (TF)-Expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC

A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer

A Study of OGX-011/Gemcitabine/Platinum-Based Regimen in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)

The Impact of Delayed Diagnosis of Alpha-1 Antitrypsin Deficiency

A Study To Determine If Two Different Versions Of Topotecan Have The Same Potency In Patients With Advanced Solid Tumors

Efficacy and Safety of Inhaled Nitric Oxide (NO) in Cystic Fibrosis (CF) Patients

Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

A Study In Pediatric Subjects With Asthma Using ADVAIR HFA, ADVAIR HFA With Spacer, And ADVAIR DISKUS

Stereotactic Body Radiation Therapy for Inoperable Locally-advanced Non-small Cell Lung Cancer

Adherence to Nintedanib Among Idiopathic Pulmonary Fibrosis Patients

Using an End-of-life Conversation Game to Engage Patients With Cancer in Advance Care Planning

Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis

Rituximab for ANCA-associated Vasculitis (RAVE) Long-Term Follow-Up Study